471A:FRA
aTyr Pharma Inc
€0.31
arrow_upward
+1.30%(+0.0040) 1D
Jun 12, 10:00:00 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 471A...
Open
€0.31
High
€0.31
Low
€0.31
Mkt. cap
42.77M
Avg. vol.
720.00
Volume
0.00
52-wk high
€5.70
52-wk low
€0.25
No. of employees
59
Open
€0.31
High
€0.31
Low
€0.31
Mkt. cap
42.77M
Avg. vol.
720.00
Volume
0.00
52-wk high
€5.70
52-wk low
€0.25
No. of employees
59
News stories
From sources across the web
Profile
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
About aTyr Pharma Inc
AI content may include mistakes. Learn more